


ContraFect

COMPANY OVERVIEW

ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant *Staph aureus* (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) *Pseudomonas aeruginosa*.



CONTRAFECT CORPORATION

28 Wells Avenue
3rd Floor
Yonkers, NY 10701
US

RECENT NEWS

ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Nov 15 2021, 7:30 AM EST

ContraFect's New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections in Patients with Cystic Fibrosis

Nov 9 2021, 7:30 AM EST

ContraFect to Present Data on the Potential of DLAs to Treat Pulmonary Infections in Cystic Fibrosis Patients

Oct 26 2021, 7:30 AM EDT

STOCK OVERVIEW

Symbol	CFRX
Exchange	Nasdaq
Market Cap	124.29m
Last Price	\$3.16
52-Week Range	\$2.97 - \$7.63

12/02/2021 04:00 PM EST

INVESTOR RELATIONS

Michael Messinger
T: 914-207-2300
mmessinger@contrafect.com

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

